Educational Webinar: Advances in HCV testing and treatment
Siemens Healthineers Haberleri | 07-10-2013
HCV infection is a significant contributor to chronic liver disease (CLD) worldwide. In the US, HCV is the leading cause of liver transplants. To address this growing threat, the CDC has recently issued a significant change to HCV screening guidelines, in order to better identify undiagnosed cases that can lead to advanced disease and missed opportunities for treatment.
At the end of the presentation, attendees will be able to:
- Describe HCV natural history and epidemiology.
- Describe the key laboratory assays involved in an HCV diagnosis.
- Understand the value in the “birth cohort” screening recommendation.
- Discuss new treatment modalities that are expected to dramatically improve treatment efficacy.
This webinar will be available for replay starting the day after the event. All who register for the event can access the webinar replay at any time.
This program has been designated for 1.0 PACE continuing education credit.1
Uluslararası (İngilizce): +49 69 797 6602 Bizi Pazartesi - Cuma günleri 8.00 - 17.00 saatleri arasında arayabilirsiniz.
There is a charge of $10.00 plus local tax for each half or full hour of CE credit. Purchase of CE credit is optional. Non-accredited participation in Siemens educational offerings and programs remains complimentary.